Abstract：【Objective】To explore the inhibitory effect of safflower polysaccharides (SPS) on the proliferation of rat liver cancer cells. 【Methods】Fifty male SD rats were randomly divided into the normal control group, the positive control group and the SPS high (135mg/kg), middle (45mg/kg) and low-dose (15mg/kg) groups, with 10 rats in each group. Rats in the normal control group were treated with gavage of normal saline, while the remaining groups were treated with gavage of 10mg/kg diethylnitrosamine (DEN) to liver establish gastric cancer models. The SPS subgroups rats were treated with gavage of different doses of SPS. After 16 weeks of intervention, all rats were sacrificed. Rat weight, tumor nodules and tumor volume were recorded. The effect of different doses of SPS (0mg/mL, 0.32mg/mL, 0.64mg/mL, 1.28mg/mL) on the growth inhibition rate (IR) of rat liver cancer CBRH-7919 cells was detected by MTT colorimetric assay. 【Results】 The rat weight in normal control group was significantly higher than those of other groups (P<0.05). Body weight of SPS subgroups was significantly higher than that of the positive control group, while the number of tumor nodules and tumor volume were significantly lower (P<0.05). The body weight of high dose group was significantly higher than that of middle and low dose groups (P<0.05), while the number of tumor nodules and tumor volume were significantly lower (P< 0.05). MTT assay showed that the inhibition rates of rat liver cancer CBRH-7919 cells at 48h and 72h after the SPS treatment were significantly higher than that of the same dose group at 24h treatment (P<0.05). When the dose of SPS was 0.64 mg/mL, the IR of rat liver cancer CBRH-7919 cells was the highest (P<0.05). 【Conclusion】SPS has inhibitory effect on liver cancer in rat and the proliferation inhibition of rat liver cancer cells in vitro as well.
李贺. 红花多糖对大鼠肝癌肿瘤大小及癌细胞生长抑制率的影响[J]. 医学临床研究, 2017, 34(2): 237-240.
LI He. Effect of Safflower Polysaccharides on Tumor Size and Cell Growth Inhibition in Rats Liver Cancer. JOURNAL OF CLINICAL RESEARCH, 2017, 34(2): 237-240.
2017, Vol. 34 
